Novavax, Inc.
NVAXNASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $1.64B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $6.20$13.39
- Volume (live)
- -
- Avg. volume (3M)
- 7.95M
Novavax (NVAX) Stock Price & Financial Analysis
Novavax Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $9.56 - $10.87 |
|---|---|
| 52-Week High | $13.39 |
| 52-Week Low | $6.20 |
| Open | $10.79 |
| Volume (last close) | 12.24M |
| Average Volume (3M) | 7.95M |
| Revenue (TTM) | 413.80M |
|---|---|
| Net Income (TTM) | -247.73M |
| Free Cash Flow (TTM) | -42.85M |
| EPS (TTM) | −$1.49 |
| Profit Margin | -59.87% |
| Operating Margin | -54.94% |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 1.64B |
|---|---|
| Shares Outstanding | 164.57M |
| Price to Sales (P/S) | 3.97 |
| Price to Book (P/B) | -8.62 |
| EV/EBITDA | -18.95 |
| 50-Day MA | $10.15 |
|---|---|
| 200-Day MA | $9.20 |
| 1-Year Change | +19.50% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Novavax at a Glance
As of the Oct 22, 2026 close, Novavax (NVAX) has a market capitalization of $1.64B. The stock trades at 4.0× sales. Over the trailing twelve months it lost $247.73M on revenue of $413.80M and burned $42.85M of free cash flow. Revenue fell 61.6% year over year.
As of its latest reported balance sheet, it holds $191.46M in cash and securities against $295.60M of debt, a net debt position of $104.14M.
Novavax does not currently pay a dividend.
The share price is up 19.5% over the past year. At $9.99 (the Oct 22, 2026 close) it sits within its 52-week range of $6.20 to $13.38, above its 200-day moving average of $9.20.
Based on 5 professional analyst ratings from the past 90 days, the consensus is Hold with an average price target of $10.75, 7.6% above the Oct 22, 2026 close.
Frequently Asked Questions About Novavax
What is the current stock price for NVAX?
As of the Oct 22, 2026 close, NVAX stock trades at $9.99. The 52-week range is $6.20–$13.39, with a day range of $9.56–$10.87.
What is the P/E ratio for NVAX?
The P/E ratio (Price-to-Earnings) for NVAX is shown in the Key Statistics section. This valuation metric helps compare Novavax, Inc. to industry peers.
Does NVAX pay dividends?
Novavax does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for NVAX?
Based on ratings from 5 professional analysts over the last 90 days, the consensus for NVAX is Hold. The average 12-month price target is $10.75, a 7.6% upside from the Oct 22, 2026 close of $9.99.
What is the market cap of NVAX?
As of the Oct 22, 2026 close, Novavax's market capitalization is $1.64B, classifying it as a small-cap company. Novavax operates in the Healthcare sector within the Biotechnology industry.